docINTERVENTIONAL CARDIOLOGY
download 
Report Transcription
INTERVENTIONAL CARDIOLOGY
Slovenia Japan Netherlands Germany Finland Sweeden Netherlands France Greece New Zealand South Korea France Finland Czech Republic Netherlands Finland Netherlands United KingdomGermany Unite States Canada New Zealand Sweeden South Korea Latvia Czech Republic Japan Switzerland Denmark Slovenia Canada United Kingdom Slovenia Sweeden P R O M E D I C A I N T E R N AT I O N A L C M E Slovenia Germany South Korea France Denmark Italy Australia Switzerland France Unite States Greece Italy Finland Australia Switzerland Latvia Norway Belgium Sweeden South Korea Czech Republic Greece Slovenia Czech Republic New Zealand Germany Italy New Zealand Switzerland Norway France Sweeden South Korea Belgium INTERVENTIONAL CARDIOLOGY 2015 Latvia Japan Norway Latvia Australia Japan Greece United Kingdom Slovenia New Zealand Switzerland Belgium Italy Denmark Germany Unite States Bulgaria Netherlands Norway Unite States Canada France Belgium Australia Japan South Korea Brazuk Bulgaria Poland Latvia Bulgaria Brazuk Japan United Netherlands Italy Kingdom Germany Hungary Netherlands Japan Croatia Latvia Denmark Bulgaria Italy Spain Finland United Kingdom Italy Norway Slovenia New Zealand New Zealand Switzerland Netherlands Finland Hungary Norway Bulgaria Belgium Poland SpainCanada Latvia United Kingdom Romania UniteLatvia States Canada Belgium Bulgaria Japan Spain Czech Republic Greece Czech Republic Russia Poland Unite States Australia Brazuk Norway Spain Slovenia Bulgaria Poland Greece Croatia Australia Greece Canada Poland Czech Republic Croatia Slovenia Hungary Poland Finland Republic of Macedonia Russia Netherlands Poland Hungary Finland Brazuk Unite States Norway Republic of Russia Macedonia New Zealand Germany Switzerland Australia Czech Republic Japan Unite States Latvia United Kingdom Denmark Greece Italy Czech Republic Denmark Brazuk Poland Finland Italy Japan Norway Croatia Romania Poland Austria Belgium Latvia Denmark Brazuk Canada United Kingdom Netherlands Latvia Greece Italy Brazuk Poland Austria Bulgaria Republic of Macedonia Poland Croatia Finland Netherlands Slovenia Latvia Norway Greece Netherlands Spain Slovenia Latvia Finland Bulgaria Latvia NorwayCzech Republic Poland Bulgaria Republic of Macedonia Austria Hungary Romania Brazuk Russia Russia Belgium Canada Greece Brazuk FinlandSlovenia Romania Republic of Macedonia Austria Bulgaria Croatia Latvia Hungary Bulgaria Romania Norway Belgium Brazuk Croatia Bulgaria Poland SpainBelgium Norway Austria Norway Belgium Republic of Macedonia Russia Czech Republic Norway Belgium Poland Austria Brazuk Spain Russia Spain Romania Spain Brazuk Croatia Republic of Macedonia Austria Croatia Romania Brazuk Poland Spain Republic of Macedonia Hungary Romania Brazuk Poland Hungary Poland Austria Russia Czech Republic Finland Spain Belgium Czech Republic Finland Latvia Croatia Spain Russia Canada Norway United Kingdom Slovenia Romania Netherlands Romania Republic of Macedonia Hungary Hungary CzechAustralia Republic United Kingdom Croatia Bulgaria Republic of Macedonia Slovenia Unite States New Zealand Australia Unite States Denmark Canada United Kingdom Greece ItalyNetherlands Czech Republic Finland BulgariaItaly Greece Slovenia Poland Spain Norway Netherlands Belgium Spain Brazuk Russia Australia New Zealand Greece Switzerland Romania Bulgaria Belgium Hungary Canada Switzerland Sweeden Spain Austria Hungary Bulgaria New Zealand Denmark Switzerland United Kingdom Germany Sweeden South Korea France South Korea Germany Australia Slovenia France Bulgaria Netherlands Romania Czech Republic Croatia South Korea Japan Australia Unite States Finland New Zealand DenmarkSwitzerland Canada United Kingdom Japan SweedenNetherlands FranceSlovenia RomaniaGermany South Korea Unite States Norway Greece BelgiumSlovenia Italy Denmark Austria Russia Brazuk Spain Latvia Australia Unite States Sweeden South Korea Japan Unite States Italy Switzerland Czech Republic FinlandUnited Kingdom Germany Japan Canada Germany Sweeden France South Korea Canada Italy Bulgaria Japan New Zealand Canada France Romania Belgium Spain Belgium Austria Hungary New Zealand Austria United Kingdom Netherlands Denmark Czech Republic Austria Russia Austria Russia Norway Croatia Greece Republic of Macedonia Netherlands Switzerland Sweeden Comprehensive Approach to the Percutaneous Management of Structural Heart Disease and Coronary and Peripheral Vascular Disease Spain UnitedBulgaria Kingdom Finland Hungary Latvia Brazuk Japan Croatia Spain Latvia Netherlands Italy Slovenia Greece Latvia Italy Brazuk Hungary Romania Russia Republic of Croatia Norway Belgium Macedonia Hungary Republic of Macedonia Italy Germany Australia Spain Republic of Croatia Austria Republic of Macedonia Macedonia Denmark Czech RepublicNorway Belgium Greece Sweeden Slovenia Finland Australia Netherlands Brazuk Poland Republic of Croatia Macedonia Latvia Finland Italy South Korea Unite Bulgaria States Austria Republic of Macedonia Denmark Unite States South Korea Brazuk France Sweeden Latvia DenmarkGreece Netherlands Switzerland Russia Japan Sweeden Norway Belgium Brazuk New Zealand Switzerland Canada Germany Switzerland Denmark United Kingdom Bulgaria Poland Germany Australia Czech Republic Slovenia Greece Denmark United Kingdom Finland UniteCanada States South Korea Spain Italy Germany Republic France of Macedonia France Poland 30TH ANNUAL INTERNATIONAL SYMPOSIUM Denmark Poland France Czech Republic Finland Republic of Croatia Macedonia Croatia Austria Hungary Russia Romania Austria Russia Spain Republic of Macedonia Republic of Macedonia Croatia Republic of Macedonia Croatia Hungary Hungary Russia Croatia Hungary Hungary Austria Russia Russia Romania Austria Austria Russia Romania Romania Hungary Russia Romania COURSE DIRECTOR James R. Margolis, MD, FACC Endorsed by the California and Colorado Chapters of the American College of Cardiology The Westin Snowmass Resort, Snowmass Village, Colorado March 1-6, 2015 Romania INTERVENTIONAL CARDIOLOGY 2015: 30 TH ANNUAL INTERNATIONAL SYMPOSIUM In January 1984, by serendipity, Andreas Grüntzig and I found ourselves alone in Snowmass for different business reasons. We took the occasion to ski together for two long and wonderful days. On the ski lifts, we talked about many things, but mostly angioplasty, as PCI was called in those days. It was from these discussions that an interventional cardiology meeting in Snowmass was born. From the outset, the purposes of this meeting were: > To explore ways to improve the still young technique, and to expand its reach. > To partner with industry in these endeavors. >To foster international cooperation and exchange of ideas, an extension of the teaching principles that Grüntzig had initiated seven years earlier. >To do all of this in a pleasant environment that encouraged camaraderie as opposed to competition. The first few meetings were quite small, consisting of didactic presentations and showing of edited videotapes from our live demonstration courses in Miami. But these early meetings adhered closely to our core objectives. It became clear that Snowmass was an excellent venue for the exchange of ideas not only in the lecture hall, but also in social venues and on ski lifts. As the meeting grew in size and stature, the European participation grew proportionately. This is how it was for 15 years. In 2000, on the advice of Patrick Serruys, we switched to the international format that persists today. It was at this time that we added participation from Japan and Korea. The international format provided an opportunity to better focus on our core values, and to keep the course fresh with a healthy turnover of young, previously undiscovered faculty and exposure to ideas and methodologies from far off lands. The new format exposed attendees to cutting edge work performed both in and outside the U.S. More importantly, with faculty from more than 25 countries on five continents the audience gained a perspective of how differing socioeconomic factors alter the performance of PCI in different cultures and different countries – usually achieving comparable results. Finally, the international format fosters, albeit in a small way, behavior conducive to world peace. In these turbulent times, academic and scientific exchanges may be useful in counteracting the rhetoric and irresponsible actions of world leaders. This year we will continue to passionately adhere to our mission while presenting an exciting didactic program combined with a celebration of thirty wonderful years in Snowmass. We will look back to see where we have been while exploring where we are going. As course director, I have had the honor and great pleasure of interacting with so many brilliant and fascinating individuals that this interaction by itself would have made it all worthwhile. During the meeting, I will introduce you to these people and recognize their contributions. Please join us for a fascinating ride from the past to the future and all that in between. James R. Margolis, MD, FACC Course Director C A L L F O R A B S T R A C T S : S U B M I S S I O N D U E D A T E J A N U A R Y 1 6 , 2 01 5 Submissions of original abstracts are being accepted for oral presentation and electronic poster display. To submit your abstracts, please visit www.promedicacme.com. K E Y T H E M E S F O R 2 01 5 Without a doubt, TAVR is the most exciting advance in interventional cardiology in recent years. Not only does the procedure work, it has been proven conclusively that it saves lives. Newer valves and newer iterations of older valves have made the procedure easier, safer and available to a rapidly expanding patient population. This year, we have devoted a major portion of our program to TAVR with more than 30 talks from operators with a combined experience of thousands of cases. These talks cover global experience, patient selection, techniques, avoidance and treatment of complications and discussion of various valves both on the market and those in clinical evaluation. Included is a seven talk mini-symposium on the Achilles heel of TAVR, neurological complications. The symposium concludes with a discussion of modalities for TVT of the mitral valve. A minor but important theme of the 2015 meeting is devoted to discussion of the meaning of one or more negative studies of treatment modalities that physicians believe are effective, despite a lack of 1A evidence. Talks in this genre start out with the title: “Is the Data Right and the Doctor Wrong, or Vice Versa?” LEARNING OBJECTIVES Upon completion of this symposium, participants should be able to: > Better understand the meaning of negative studies. > Gain a comprehensive picture of TAVR. > Integrate advances in electrophysiology into their practice. > Better manage complications of coronary and peripheral percutaneous interventions. > Discuss the controversies surrounding the indication for coronary stents, efficacy, and complications. >G ain an international perspective of percutaneous interventions including the effect of a country’s economics on how interventions are performed. C M E AC C R E D I TAT I O N A N D D E S I G N AT I O N Promedica International CME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Promedica International CME designates this live activity for a maximum of 30.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Provider approved by the California Board of Registered Nursing, Provider #8495 for 30.5 contact hours. The American Board of Cardiovascular Perfusion (ABCP) has approved this symposium for a maximum of 27.2 Category 1 CEUs for Sunday, March 1 (5.4 CEUs), Monday, March 2 (5.0 CEUs), Tuesday, March 3 (5.4 CEUs), Wednesday, March 4 (4.8 CEUs), Thursday, March 5 (4.6 CEUs), and Friday, March 6 (2.0 CEUs). E U R O P E A N AC C R E D I TAT I O N Due to a mutual recognition between the AMA and the UEMS, European participants may convert AMA Category 1 Credits. AC T I V I T Y E VA L UAT I O N Evaluation by online questionnaire will address content, presentation and future educational needs. COMMERCIAL SUPPORT This program is supported, in part, by educational grants and exhibits from industry, in accordance with the ACCME Standards for Commercial Support. At the time of printing, a complete list of commercial supporters was not available. Appropriate acknowledgement will be given to all supporters in meeting materials onsite. COURSE DIRECTORS AND FACULTY COURSE DIRECTOR James R. Margolis, MD, FACC USA C OURSE CO-DIRECTORS Dariusz Dudek, MD, PhD Poland Osamu Katoh, MD Japan Jacques J. Koolen, MD, PhD The Netherlands Martin B. Leon, MD, FACC USA M. Pauliina Margolis, MD, PhD USA/Finland Seung-Jung Park, MD, PhD, FACC South Korea Augusto D. Pichard, MD, FACC USA Nicolaus Reifart, MD, FACC Germany SCIENTIFIC COMMITTEE Jorge Belardi, MD, FACC Argentina Patrick Kay, MD, PhD New Zealand Hideo Nishikawa, MD, PhD Japan Marko Noc, MD, PhD Slovenia Michael Pieper, MD Switzerland Kari I. Saunamäki, MD, PhD Denmark Robert S. Schwartz, MD USA Gerald S. Werner, MD, PhD, FACC Germany FACULTY Kevin Abrams, MD USA Takashi Akasaka, MD Japan Yolande Appelman, MD, PhD The Netherlands Stanislaw Bartus, MD, PhD Poland Andreas Baumbach, MD United Kingdom Diego F. Belardi, MD Argentina Brian T. Bethea, MD USA Guus Brueren, MD, PhD The Netherlands Leszek Bryniarski, MD, PhD Poland Matjaz Bunc, MD, PhD Slovenia Mark W. Burket, MD, FACC USA Pawel E. Buszman, MD, PhD, FACC Poland Piotr P. Buszman, MD, PhD Poland David Clark, MBBS Australia Peter Clemmensen, MD, DMSc Denmark Justin Davies, MD, PhD United Kingdom Pieter den Heijer, MD, PhD The Netherlands Willem Dewilde, MD The Netherlands Pieter A. Doevendans, MD, PhD The Netherlands Thomas Engstrøm, MD, PhD, DMSci Denmark Andrjes Erglis, MD, PhD, FACC Latvia Witold Gerber, MD, PhD Germany Robert J. Gil, MD, PhD Poland Luis Guzmán, MD, FACC USA Michal Hawranek, MD, PhD Poland Timothy D. Henry, MD, FACC USA Richard R. Heuser, MD, FACC USA Gerhard Hindricks, MD, PhD Germany Ota Hlinomaz, MD, PhD Czech Republic Kurt Huber, MD, FACC Austria Nikolaj Ihlemann, MD, PhD Denmark Charles Ilsley, MD United Kingdom David Gareth Jones, BSc(Hons), MBBS, MD(Res) United Kingdom Petr Kala, MD, PhD Czech Republic Zbigniew Kalarus, MD, PhD Poland David Kallend, MBBS USA Anne Kaltoft, MD, PhD Denmark Samir Kapadia, MD, FACC USA Dimitri Karmpaliotis, MD, PhD, FACC USA Sasko Kedev, MD, PhD, FACC Republic of Macedonia Hyo-Soo Kim, MD, PhD South Korea Young-Hak Kim, MD, PhD South Korea Karel T. Koch, MD, PhD The Netherlands Bon-Kwon Koo, MD, PhD, FACC South Korea Hans Krankenberg, MD Germany Alexandra Lansky, MD, FACC USA Jens Flensted Lassen, MD, PhD Denmark Seung-Whan Lee, MD, PhD South Korea Jacek Legutko, MD, PhD Poland Maciej Lesiak, MD, PhD Poland Michael J. Mack, MD, FACC USA Hooman Madyoon, MD, FACC USA Raj Makkar, MD, FACC USA Kambis Mashayekhi, MD Germany Mark Mason, MD United Kingdom Evgeny Merkulov, MD, PhD Russia Markus Meyer-Gessner, MD Germany Krzysztof Milewski, MD, PhD Poland Vsevolod Mironov, MD Russia Jeffrey W. Moses, MD, FACC USA Blaz Mrevlje, MD Germany Christoph A. Nienaber, MD, PhD Germany Andrzej Ochala, MD Poland Lisette Okkels Jensen, MD, DMSci Denmark Aleksander G. Osiev, MD, PhD Russia Duk-Woo Park, MD, PhD South Korea Radoslaw Parma, MD, PhD Poland Hrvoje Pintarić, MD, PhD Croatia Christopher Piorkowski, MD Germany Mark Pitney, MBBS Australia Aleksey Protopopov, MD Russia Ðeiti Prvulović, MD Croatia Maria Radu, MD, PhD Denmark Tomasz Rakowski, MD, PhD Poland Hanne Berg Ravn, MD, PhD Denmark Michael J. Rinaldi, MD, FACC USA Jamil A. Saad, MD, FACC Brazil Katherine Shreyder, MD, PhD Russia Andre R. Simon, MD, PhD United Kingdom Pieter Smits, MD, PhD The Netherlands Grzegorz Smolka, MD, PhD Poland Helle Søholm, MD, PhD Denmark Philipp Sommer, MD Germany Dace Sondore, MD Latvia Jong-Min Song, MD, PhD South Korea Hans Störger, MD Germany Karlis Strenge, MD Latvia Gunnar Tepe, MD Germany Pim A.L. Tonino, MD, PhD The Netherlands Etsuo Tsuchikane, MD, PhD Japan Kazushi Urasawa, MD, PhD Japan BJL Van den Branden, MD, PhD The Netherlands Jan Van der Heyden, MD, PhD The Netherlands Hans-Friedrich Voehringer, MD Germany Robert A. Vogel, MD, FACC USA Szilard Voros, MD, FACC USA Kristian Wachtell, MD, PhD, FACC Denmark Darren L. Walters, MBBS, MPhil Australia Timothy Watson, MD New Zealand Steven K. White, BSc, MBChB United Kingdom Andrew Wilson, MBBS, PhD Australia Adam Witkowski, MD, PhD Poland Wojciech Wojakowski, MD, PhD Poland Lucian Zarma, MD Romania S C I E N T I F I C P R O G RBulgaria A M 2 0 15 Brazuk Spain S U N D AY, M A R C H 1 7:00 – 10:00 AM Republic of Macedonia MORNING SESSION Croatia Austria RUSSIAN SESSION Sweeden ea d Poland AUSTRALIA/ NEW SESSION Zealand ZEALAND Sweeden SouthNew Korea Hungary Chairman: Patrick Kay, MD, PhD s Switzerland Australia dom Unite States Canada New Zealand Australia Controversies in the Use of FFR Andrew Wilson, MBBS, PhD Treating Shock in the Elderly Canada David Clark, MBBS United Kingdom Slovenia Radiation in the Cathlab: Slovenia Angles, Projections, Positions – Do They Really Matter? Mark Pitney, MBBS Greece Czech Republic Finland Belgium Czech Republic Necessity is the Mother of Invention Timothy Watson, MD Norway Belgium Brazuk Hypertension: Is There Still Room for a NonBrazuk Poland pharmacological Approach? Patrick Kay, MD, PhD Initial Experience with the Lotus Transcatheter Aortic Valve Implantation System: What Do Newer Croatia Austria Generation Devices Bring Romania to the TAVI Table? Darren L. Walters, MBBS, MPhil Spain Austria Russia Romania 3:30 – 6:00 PM France AFTERNOON SESSION South Korea Sweeden Chairman: Evgeny Merkulov, MD, PhD AMERICAN SESSION I: TAVR SESSION, PART I Current Situation with LAA Closure Procedures in Russia: Experience with Complex LAA Closure Cases Evgeny Merkulov, MD, PhD Chairmen: Michael J. Mack, MD, FACC, and Augusto D. Pichard, MD, FACC Russia Romania Germany Japan Denmark Grace-score Predicts Short and Long-term Mortality but Overestimates the Mortality Risk in ACS Patients Treated with PCI of LM Stenosis Katherine Shreyder, MD, PhD Italy Netherlands Fractional Flow Reserve Measurement for Decision Making in Multivessel Flow and Diffuse Coronary Artery Disease Vsevolod Mironov, MD Latvia Bulgaria Hybrid and Pure Endovascular Approaches in Patients with Aortic Dissections and Aneurysms Aleksey Protopopov, MD, PhD Republic of Macedonia How to Improve Support during CTO PCI Aleksander G. Osiev, MD, PhD Hungary Retrograde CTO PCI in the US: A Magnificent Journey Dimitri Karmpaliotis, MD, PhD, FACC Venous Disease, the Missing Link…An Update Hooman Madyoon, MD, FACC Switzerland Unite States United Kingdom New Zealand Australia Canada Global Results of TAVR Martin B. Leon, MD, FACC Greece Slovenia Finland Czech Republic Current Status of TAVR in US and Future Prospects; Update on the PARTNER Trials; US TVT Registry Michael J. Mack, MD, FACC Outcomes on Inoperable Patients Raj Makkar, MD, FACC Norway Poland Belgium Brazuk CoreValve: Pros and Cons Augusto D. Pichard, MD, FACC Spain Patient Selection for TAVR Augusto D. Pichard, MD, FACC Alternative Access for TAVR Michael J. Mack, MD, FACC Croatia Austria Preventing Vascular Complications Samir Kapadia, MD Russia Romania Conscious Sedation for TAVR Augusto D. Pichard, MD, FACC AV Block and PPM after TAVR Raj Makkar, MD, FACC TAVR for Pure AR Augusto D. Pichard, MD, FACC AR Complicating TAVR: How to Prevent and How to Treat Samir Kapadia, MD Transcatheter Mitral Valve Innovations, Part I Brian T. Bethea, MD In celebration of our 30th anniversary, each day we will look back over the past 30 years including video of live cases from the 90’s, slide presentations from past meetings, and a little bit of nostalgia. S C I E N T I F I C P R O G R A M 2 015 Greece Italy Netherlands M O N D AY, M A R C H 2 Finland Latvia 7:00 – 10:00 AM Norway MORNING SESSION South Korea Switzerland Bulgaria New Zealand Poland Unite States Australia Spain New Aortic Valve Devices Michael J. Mack, MD, FACC Canada Republic of Macedonia MINI-SYMPOSIUM ON NEUROPROTECTION Greece Stroke in TAVR: Is it a Deal Breaker? Samir Kapadia, MD Croatia Slovenia Hungary Finland Czech Republic France South Korea SOLACI SESSION Switzerland Brazuk Unite States Belgium Germany Sweeden AMERICAN SESSION II United Kingdom Slovenia Russia STEMI in Latin America: Challenges to Match Established Standards of Care Chairman: Jorge Belardi, MD, FACC Japan Denmark United Kingdom Finland Czech Republic Norway Wearable Cardiac Defibrillators as a Bridge to ICD Post STEMI: What is the Evidence behind It? Diego F. Belardi, MD Brazuk Impact of MRI Methodology on DWI MRI Lesion Volume Measurements and Statistical Implications Szilard Voros, MD, FACC Spain Croatia Austria Neuroprotection: Importance of Covering All Three Cerebral Vessels; Lessons from DEFLECT 1 and 2 Andreas Baumbach, MD Russia Romania Cerebral Protection Devices: Deflection vs. Capture; Pros and Cons Jeffrey W. Moses, MD, FACC Update on Keystone Heart Clinical Program and Results Alexandra Lansky, MD, FACC France MR and TAVR Augusto D. Pichard, MD, FACC Germany Valve in Valve for Degenerated Bioprosthetic Aortic and Mitral Valves Samir Kapadia, MD Japan Denmark Transcatheter Mitral Innovations, Part II Michael J. Mack, MD, FACC Italy Netherlands Latvia Bulgaria Bulgaria Poland France Spain Germany Japan 3:30 – 6:00Denmark PM AFTERNOON SESSION Hungary Russia ORAL ABSTRACT SESSION I New Technology for DEBs Piotr P. Buszman, MD, PhD, FACC Italy Greece Netherlands Finland A Controlled Local Drug Delivery for Plaque Treatment with Polymer Microspheres Krzysztof Milewski, MD, PhD Latvia Norway KOREAN SESSION Bulgaria Poland Chairman: Seung-Jung Park, MD, PhD, FACC South Korea Sweeden Spain Optimal Stenting Strategy for Bifurcation Coronary Lesions: Lessons from the CROSS and PERFECT Trials Young-Hak Kim, MD, PhD Switzerland New Zealand Republic of Macedonia Unite States Croatia Australia Hungary Canada Russia Changing Paradigm in Bifurcation Intervention Using the Contemporary DES: Lessons from the Korean Bifurcation Registry Hyo-Soo Kim, MD, PhD United Kingdom Greece Slovenia Finland Czech Republic Temporal Changes of PCI vs. CABG for Left Main Disease Seung-Jung Park, MD, PhD, FACC Norway Poland Spain Belgium Brazuk United Kingdom United Kingdom New Zealand New Zea Australia Australia Canada Canada Greece Greece Slovenia Slovenia Finland Finland Czech Republic Czech Re 3D Echocardiography-guided Percutaneous Transcatheter Closure of Atrial Septal Defect Jong-Min Song, MD, PhD Latvia Latvia New Zealand Switzerland United Kingdom Unite States Unite States Sweeden Sweeden Sweeden South Korea Croatia Italy Netherlands Netherlands Brazuk Switzerland Switzerland CT-derived Hemodynamic Assessment: Current and Future Applications Bon-Kwon Koo, MD, PhD, FACC Italy Belgium Austria Norway Norway Current TAVI: SAPIEN XT vs. Core Valve Seung-Jung Park, MD, PhD, FACC Australia Unite States Republic of Macedonia Japan Denmark Denmark Romania South Korea South Korea Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation for Off-Label vs. On-Label Indication Duk-Woo Park, MD, PhD Netherlands The New Paradigm in the Treatment of Acute MI Luis A. Guzmán, MD, FACC France Germany Germany Canada Slovenia DWI MRI Lesions as Surrogates of Cognitive Dysfunction Kevin Abrams, MD Poland France Greece STEMI in Brazil: National Registries Jamil A. Saad, MD, FACC Belgium Australia Italy Austria Carotid Artery Compression Theory Robert S. Schwartz, MD, FACC Norway Atherosclerotic Burden and its Clinical Impact of Asymptomatic Diabetes According to Risk Stratification Seung-Whan Lee, MD, PhD New Zealand Japan STEMI: Stent for Life Program in Argentina Jorge Belardi, MD, FACC Latvia Czech Republic Sweeden Bulgaria Bulgaria BALKAN SESSION Canada Poland Poland Spain Spain Belgium Belgium Brazuk Brazuk Austria Austria Romania Chairmen: Marko Noc, MD, PhD, and Sasko Kedev, MD, PhD, FACC Slovenia Republic ofRepublic of MacedoniaMacedonia Croatia Croatia Czech Republic Stroke Prevention in the Hands of Interventional Cardiologists? Marko Noc, MD, PhD Hungary Hungary Russia Russia Belgium Wrist Access (Radial and Ulnar) as a Primary Approach for Carotid Artery Stenting Sasko Kedev, MD, PhD, FACC Brazuk TAVR in the Balkans Matjaz Bunc, MD, PhD Austria STEMI Cooling after CHILL MI: Case Closed? Marko Noc, MD, PhD Romania Differences in sVCAM-1 in Patients Undergoing Stenting and Paclitaxel-coated Balloon Ðeiti Prvulović, MD Cardiogonimetry: Do we need Another Non-invasive Diagnostic Method for Suspected CAD in Women Prior to Coronary Angiography? Hrvoje Pintarić, MD, PhD Romania Roman France Germany New Zealand Sweeden Switzerland South Korea France Japan Germany Unite States Switzerland Japan Australia Unite States Canada United Kingdom France T U E S D AY, M A R C H 3 Denmark 7:00 – 10:00 AM Canada United Kingdom Germany Monday Evening Session Greece Slovenia DenmarkItaly Lagniappe SESSION MORNING Italy South Korea – Greece Finland Japan Switzerland New Zealand Japan Unite States Australia Sweeden Follow-up Results of the Percutaneous Septal Sinus Shortening (the MVRx System) for the Treatment of Functional Mitral Regurgitation Andrejs Erglis, MD, PhD, FACC Switzerland Unite States Slovenia Czech Republic Latvia Bulgaria Finland Norway Australia Norway Poland Italy BelgiumBrazuk Optimal Uptake Area for the STEMI Network: Time for a Change? Perspectives from a Single MEGA Center Peter Clemmensen, MD, DMSc Poland Spain France Netherlands Brazuk Croatia United Kingdom Netherlands Greece Latvia Hungary Russia Norway Russia Japan FranceRomania Republic of Macedonia Denmark Japan HungaryItaly Implications of Left Ventricular Hypertrophy in STEMI Patients Treated Denmark with Primary PCI Thomas Engstrøm, MD, DMSci, PhD Netherlands Latvia Italy Primary PCI in Patients with STEMI and Pre-hospital Cardiac Arrest – Netherlands Why Some People Arrest and Others Do Not Helle Søholm, MD Latvia Bulgaria Cause and Time of Death Associations in Patients Bulgaria Treated with Percutaneous Coronary Intervention for Non ST-Elevation Myocardial Infarction Kristian Wachtell, MD, PhD Republic of Macedonia Hungary Novel Technique for Distal of LMCA Lesions UsingRepublic DES and Macedonia ABSORB: One-year Follow-up Dace Sondore, MD Hungary Coronary OCT – Quo Vadis? Maria Radu, MD, PhD The Nordic Dedicated Bifurcation Stent Study – Rationale and Design Jens Flensted Lassen, MD, PhD United Kingdom Poland Greece New Zealand Switzerland Spain Republic of Macedonia Latvia Very Late Sweeden Stent Thrombosis: Updates from the SORT OUT Program New Zealand Switzerland Lisette Okkels Jensen, MD, DMSci Hungary Bulgaria Austria United Kingdom Belgium Canada Brazuk Slovenia Finland Croatia Norway Czech Republic Austria Belgium Australia Unite States South Korea Croatia Australia CENTRAL/EASTERN EUROPEAN SESSION II Coronary Revascularization in Stable Angina Netherlands Brazuk Right Ventricular Failure and Mechanical Support Hanne Berg Ravn, MD, PhD Czech Republic Spain Sweeden South Korea Poland New Zealand Stem Cells in CV Disease – We Need Second Generation Cell Products! Wojciech Wojakowski, MD, PhD Belgium Renal Denervation after HTN3 Anne Kaltoft, MD, PhD Romania How to Improve the Present Good Outcome of STEMI? LookingGermany for High-risk Subgroups Kari I. Saunamäki, MD, PhD Norway Italy Austria Germany Unite States Czech Republic Bulgaria Sweeden Slovenia ACS in Patients Less Than 45 Years Old Robert J. Gil, MD, PhD Slovenia Finland Primary PCI in Latvia: Lessons from Registry of Latvia Acute Coronary Syndrome Karlis Strenge, MD, PhD Croatia Finland Japan France Republic of Macedonia Hungary Switzerland Canada Transcatheter Mitral Valve Implantation: Experience from the First In-human Cases Nikolaj Ihlemann, MD, PhD, Lars Søndergaard, MD, DMSc, Susanne Holme, MD, and Peter Bo Hansen, MD Austria Bulgaria South Korea Canada Bioresorbable Scaffolds for PCI in ACS – In-hospital and Long-term Outcomes Dariusz Dudek, MD, PhD Greece Denmark Latvia Spain Republic of Macedonia United Kingdom Germany Czech Republic Denmark Belgium Chairmen: Andrejs Erglis, MD, PhD, FACC, M. Pauliina Margolis, MD, PhD, and Kari I. Saunamäki, MD, PhD Bulgaria Change in the Landscape of Antiplatelet Treatment in ACS Tomasz Rakowski, MD, PhD New Zealand Italy Latvia Netherlands Sweeden Germany Denmark SCANDINAVIAN SESSION Netherlands South Korea Australia New Zealand Canada Russia Brazuk Romania Chairmen: Dariusz Dudek, MD, PhD, Jacek Legutko, MD, PhD, and Lucian Zarma, MD Poland Spain – 6:00Australia PM Unite3:30 States Greece Slovenia Romania Russia AFTERNOON SESSION Republic of Macedonia CENTRAL/EASTERN Canada EUROPEAN SESSION I Urgent and Elective Coronary Revascularization Greece Slovenia United Finland Kingdom Norway Czech Republic Belgium Hungary Brazuk Chairmen:Czech Republic Dariusz Dudek, MD, PhD, Petr Kala, MD, PhD, Norway Belgium and Jacek Legutko, MD, PhD Finland Poland Spain Acute Coronary Syndromes Brazuk in 2015: Update on Logistics, Treatment, and First vs. Second Generation DES Spain in High-risk ACS Patients: Katowice-Zabrze Registry of 2000 patients Wojciech Wojakowski, MD, PhD Croatia Austria Poland Croatia Russia Russia Austria Romania Stent for Life Initiative Achievements in STEMI Patients in Europe and Beyond Romania Petr Kala, MD, PhD Stent for Life Initiative in Poland – Update on Logistics and Clinical Outcomes in STEMI and NSTE ACS Jacek Legutko, MD, PhD IVUS-guided Bifurcation Stenting – New Insights from the BLAST and Other Studies Jacek Legutko, MD, PhD Croatia Austria Safety and Efficacy of the New Generation Bifurcation Dedicated Stent BiOSS LIM – Final Results of the POLBOS II Study Robert J. Gil, MD, PhD Russia Romania Breaking the Limits or Just Breaking the Struts? One-year Clinical and Angiographic Outcomes after Implantation of Bioresorbable Scaffolds in Coronary Bifurcation Lesions Maciej Lesiak, MD, PhD First In-man Experience with New Microcatheter NovaCross™ in Chronic Total Occlusions Leszek Bryniarski, MD, PhD France South Korea Sweeden S C I E N T I F I C P R O G R A M 2 0 15 Germany TU E S DAY c ont inu ed One-year Clinical and Angiographic Outcomes after Implantation of Bioresorbable Scaffolds in Chronic Total Occlusions Maciej Lesiak, MD, PhD Coronary Revascularization before TAVI / Mitral Interventions – When and How? Dariusz Dudek, MD, PhD Hybrid Coronary Revascularization for Multivessel Disease – Should it be a Common or Niche Strategy? New Insights from the HYBRID Trial Michal Hawranek, MD, PhD Hybrid Coronary Revascularization for Multivessel Disease – Would Novel Antiplatelet and Antithrombotic Compounds Become a Mainstream Strategy for the Future? Krzysztof Milewski, MD Switzerland New Zealand WE DNE SDAY,UniteMStates ARCH 4 Australia United Kingdom 7:00 – 10:00 AM Canada Japan Denmark MORNING SESSION Greece DUTCH SESSION Italy Slovenia Czech Republic Finland Chairman: Jacques J. Koolen, MD, PhD Netherlands What Innovations in Norway Belgium Coronary Artery Disease will Change the Future? Patrick W. Serruys, MD, PhD Brazuk Bulgaria Poland Latvia Edwards Sapien XT vs Edwards Sapien 3 Spain Guus Brueren, MD, PhD Multivessel Disease Experience from FAME 1, 2, and 3 Republic of Croatia Pim A.L. Tonino, MD, PhDAustria Macedonia Single Center Experience with Absorbable Stents: Hungary What is OurRussiaIndication? Romania Jacques J. Koolen, MD, PhD Paravalvular Leakage after TAVR Peter den Heijer, MD, PhD Mitral Valve Clipping: An Update BJL Van den Branden, MD, PhD DES or BMS in Patients on Long-term Anticoagulants Who Need PCI? Willem Dewilde, MD First European Experience with Novel Hypertension Treatment Jan Van der Heyden, MD, PhD Which Patients Benefit from Bioreabsorbable Scaffolds? The Five-year Maasstad Hospital Experience and Introduction to the Multicenter COMPAREABSORB Trial Pieter Smits, MD, PhD The Heart of Women: Playing Hard to Get? Yolande Appelman, MD, PhD MicroRNA’s Provide an Optimal Target to Change Cardiovascular Function Pieter A. Doevendans, MD, PhD Final Two-year Results of the APPOSITION III Study Evaluating the Use of the STENTYS Self-apposing Stent for the Treatment of ST-Segment Elevation Myocardial Infarction in the Setting of Primary PCI Karel T. Koch, MD, PhD Predicting the EXCEL Results from the SYNTAX Score II Patrick W. Serruys, MD, PhD 3:30 – 6:00 PM France South Korea Sweeden AFTERNOON SESSION Switzerland JAPANESE SESSION Germany Japan New Zealand Australia Chairmen: Osamu Katoh, MD, Hideo Nishikawa, MD, PhD Unite States CTO-PCI: Past,UnitedPresent Kingdom and the Future Osamu Katoh, MD Denmark Canada CTO-PCI Registry in JapanSlovenia Etsuo Tsuchikane, MD, PhD Italy Greece Finland CTO Guide PCIf Takashi Akasaka, MD Netherlands Czech Republic My Style of EVT Norway Belgium Kazushi Urasawa, MD, PhD Latvia Recent Japanese Clinical Trials Poland MD, PhDBrazuk Hideo Nishikawa, Bulgaria Spain Republic of Macedonia Hungary Croatia Russia Austria Romania Netherlands South Korea Latvia Switzerland New Zealand Norway Bulgaria Germany Australia BRITISH SESSION Germany Japan 7:00 – 10:00 AM Switzerland Poland Sweeden Brazuk Lessons Learned or To Be Learned from Randomized Trials with BRS Patrick W. Serruys, MD, PhD New Zealand Sweeden South Korea Japan Canada South Korea MORNING SESSION France Target vs. Total Revascularization in PCI Charles Ilsley,Slovenia MD Greece Belgium T H U R S D AY, M A R C H 5 France Unite States United Kingdom Czech Republic Finland Sweeden Spain States AMERICANUniteSESSION IIIAustralia Switzerland New Zealand A LITTLE BIT OF SouthEP Korea France Denmark Unite States Republic of Macedonia UnitedAustralia Kingdom Croatia The Future of TAVR Acute Physiologic Martin B. Leon, MD, FACC Measurements during Primary Italy Greece Slovenia Czech Republic Finland Stem Cells: State of the Union PCI to Predict Final Infarct Size Hungary Russia Romania Timothy D. Henry, MD, FACC Andreas Baumbach, MD Czech Republic Netherlands Finland Cents (sic) What Makes for Fusion Mapping Norway Belgium of Treating Superficial Femoral Physiology and Anatomy (IVUS/Angiography) to Guide Latvia Disease in 2015: Balloons, Belgium Stents, or Norway Atherectomy? Clinical Decision Making Brazuk Poland Mark W. Burket, MD, FACC Justin Davies, MD, PhD Sympathetic Denervation: Brazuk Acute Cardiac Support: Bulgaria Poland Spain Are the Data Right and the Current Role of LVAD Doctor Wrong, or Vice Versa? and VA ECMO James R. Margolis, MD, FACC Spain Andre R. Simon, MD, PhD Denmark United Kingdom Canada Italy Greece Slovenia Netherlands Finland Czech Republic Latvia Bulgaria Croatia Austria Human Factors in Acute Cardiac Care Mark Mason, MD Norway Poland Belgium Brazuk PFO Closure: Are the Data Right and the Doctor Wrong, Vice Versa? Republic or of Croatia Austria Macedonia James R. Margolis, MD, FACC Spain Sweeden AustriaCanada Germany Switzerland New Zealand Fighting Sudden Cardiac Death Over the Last Three Japan Australia Unite States Decades: Progress and Challenges Gerhard Hindricks, MD, PhD Denmark United Kingdom Canada Heart Failure and Cardiac Implants: Resynchronization and Novel Approaches Greece Italy Slovenia Christopher Piorkowski, MD Catheter Ablation of Finland Ventricular Tachycardia inCzech Republic Patients with Organic Heart Disease: Can We Replace Latvia Norway Belgium the ICD? Philipp Sommer, MD Netherlands Brazuk Bulgaria Poland Romania CRRISiS in the Cath Lab: 3:30 – 6:00 PM Stable Angina: Are the Data Simulated Emergency Training AFTERNOON SESSION the Doctor Wrong, David Gareth Jones, BSc(Hons), Hungary Right and Russia Romania Spain or Vice Versa? MBBS, MD(Res) GERMAN SESSION Sweeden Sweeden France France South Korea South Korea Jeffrey W. Moses, MD, FACC The Future of Infarct What is the Etiology of Imaging? ...New Insights New Zealand New Zealand Germany Germany Switzerland Switzerland Arteriosclerosis: A DNA Republic of Croatia Austria Chairmen: from PET-MRI Macedonia Analysis of Receptive Plaque Nicolaus Reifart, MD, FACC, and Steven K. White, BSc, MBChB Richard R. Heuser, MD, FACC Japan Japan Gerald S. Werner, MD, PhD, FACC Australia Australia Unite States Unite States Should We Lose Faith in Left Atrial Appendage Closure Concepts forRussiathe Treatment Renal Denervation? Early Hungary Romania Michael J. Rinaldi, MD, FACC of SFA In-stent Restenosis Findings Evaluating the Denmark Denmark Canada Canada United Kingdom United Kingdom Hans Krankenberg, MD Reduction in Blood Pressure Precision Phenotyping and in Pharmacological Controlled Panomics for Biomarker and Ascending Aorta: A New Field Subjects Undergoing Distal Drug Target Discovery: The for Endovascular Treatment? Greece Greece Italy Italy Slovenia Slovenia and Branch Renal Artery GLOBAL Study Hans Krankenberg, MD Denervation Szilard Voros, MD, FACC Cardiac MRI 20 Years Later Justin Davies, MD, PhD Czech Republic Netherlands Netherlands Finland Finland New Era in Lipid Michael Pieper, MD Czech Republic Management? 25 Years Experience in CTO Robert A. Vogel, MD, FACC Latvia Latvia PCI: 5-Years Inspired by Norway Norway Belgium Belgium PCSK9 Inhibition: EURO-CTO-CLUB New Approach to Lipid Markus Meyer-Gessner, MD Management Brazuk Brazuk Bulgaria Bulgaria Early and Poland LatePoland Management David Kallend, MD of Aortic Dissection Dual or Triple Therapy Christoph A. Nienaber, MD, PhD Spain Spain for PCI Patients with Monitored Euro-CTO Registry: Atrial Fibrillation A New Concept to Improve Kurt Huber, MD, FACC Quality Data Republic of Republic of Croatia Croatia Austria Austria Nicolaus Reifart, MD, FACC MacedoniaMacedonia Russia Republic of Macedonia Hungary Croatia Russia Austria Romania Hungary Hungary Russia Russia Romania Romania S C I E N T I F I C P R O GGermany R A M 2 0 15 New Zealand Switzerland France Japan South Korea Australia Unite States Germany T H U R S DAY c on t inu ed Denmark Severe Calcification as a Predictor of Outcome of DCB Treatment in Peripheral Arteries: Results of a Blinded Core Lab Analysis and a Possible Way to Overcome this Issue with Atherectomy, BTK Study Concept Gunnar Tepe, MD Italy Netherlands Latvia The Impact of CTO on Mortality in STEMI PCI: Results of a Prospective Multicentre Study of More than 12,000 Patients (FITT-STEMI) Gerald S. Werner, MD, PhD, FACC Bulgaria Republic of Macedonia Clinical Important Drug Interactions in Cardiovascular Catheterizations and Interventions Hans-Friedrich Voehringer, MD Hungary Guiding the PCI in ACS: From IVUS to OCT Blaz Mrevjle, MD Current Status of Interventional Treatment of Calcified Coronary Lesions Hans Störger, MD Sweeden Switzerland New Zealand Unite States Australia F R I D AY, M A R C H 6 United Kingdom Japan Canada 7:00 – 10:00 AM MORNING SESSION Greece DenmarkSlovenia United Kingdom CENTRAL/EASTERN EUROPEAN SESSION III Interventional Cardiology beyond Coronary Revascularization Finland Norway Italy Czech Republic Belgium Netherlands Latvia Brazuk Spain Bulgaria Slovenia Finland Czech Republic Norway Poland Beyond Revascularization for Ischemic Heart Disease: Significance of Mitral Regurgitation and Mitral Valve Repair Witold Gerber, MD, PhD Spain Croatia Russia Austria Republic of Macedonia Romania Croatia TAVI in Intermediate Risk Patients Adam Witkowski, MD, PhD Hungary Canada Greece Chairmen: Dariusz Dudek, MD, PhD, Andrzej Ochala, MD, and Adam Witkowski, MD, PhD Poland The ROX Coupler: Creation of a Fixed Central Arterial-Venous Anastomosis for the Treatment of Systemic Arterial Hypertension Adam Witkowski, MD, PhD Russia Feasibility and Clinical Outcomes of TAVI in Difficult Subsets: Bicuspid Aortic Valve, Valve-in-valve Implantations Radoslaw Parma, MD, PhD Immediate and Long-term Outcomes after TAVI in Poland – POLTAVI Registry New Generation TAVI Dariusz Dudek, MD, PhD, Adam Witkowski, MD, PhD Incidence, Predictors and Outcome of VARC2-defined Acute Kidney Injury after TAVI Andrzej Ochala, MD Percutaneous Treatment of Mitral Valve Dariusz Dudek, MD, PhD Transcatheter Closure of Paravalvular Leaks Grzegorz Smolka, MD, PhD Revascularization Strategies in STEMI in Very Old Patients with Multivessel Disease Lucian Zarma, MD Is There a Place for New Generation Percutaneous Devices Designated for the Treatment of Resistant Hypertension? Krzysztof Milewski, MD, PhD Belgium Safety and Performance of Urinary Bladder Electrical Stimulation in Acute Decompensated Heart Failure Andrejs Erglis, MD, PhD Brazuk Low/High Energy Stimulation to Improve Long-term Outcome after Revascularization in Patients with Ischemic Heart Failure Zbigniew Kalarus, MD, PhD Austria Romania Advanced Techniques for Recanalization of Peripheral Arteries Stanislaw Bartus, MD, PhD Advanced Strategy for Revascularization of High-risk Patients with Multivessel, Diffuse Coronary Artery Lesions Pawel E. Buszman, MD, PhD, FACC Discussion & Summary REGISTRATION AND HOTEL INFORMATION L O C AT I O N H OT E L AC C O M M O DAT I O N S The Westin Snowmass Resort Snowmass Village, Colorado A block of rooms has been reserved at the Westin Snowmass Resort and in limited quantities at the adjacent Wildwood Snowmass. Please contact the hotel directly for room reservations at 800-525-9402 or 970-923-3520. In order to receive the special rates below, you must mention the Interventional Cardiology 2015 symposium. Reservations must be received by the Westin Snowmass Resort no later than end of business day, February 6, 2015. R E G I S T R AT I O N Physician/Industry $1,050 through January 16, 2015 $1,250 after January 16, 2015 Resident/Fellow/Nurse $550 through January 16, 2015 $750 after January 16, 2015 Please make checks payable to Promedica International CME in US dollars drawn on a US bank. Visa, MasterCard, American Express and Discover cards are also accepted. Please register online at www.promedicacme.com. If you prefer, you may complete the form below and mail or fax it to: Promedica International CME 300 Carlsbad Village Drive, Suite 108A-326 Carlsbad, CA 92008 Tel: (760) 720-2263 Fax: (760) 720-6263 Email: [email protected] Special rates for Interventional Cardiology 2015 participants are below. Please note that a resort fee and applicable taxes will be added to the nightly rates. $345 Westin Alpine Room (king) $375 Westin Deluxe Pinnacle Room (2 queens or king) $395 Westin Premium Pinnacle Room (2 queens or king) aka “Slopeview” $199 Wildwood Room (2 doubles or king) All reservations must be guaranteed and accompanied by a deposit of 25% of the total room night revenue at the time of booking. The balance is due 30 days prior to arrival. REFUNDS All cancellations must be submitted in writing and refunds will be subject to a $100 administration charge. Cancellations cannot be accepted over the telephone. Refunds will not be available after January 16, 2015. CONFERENCE PRODUCED BY PROMEDICA INTERNATIONAL CME Look for continuous updates on our website at www.promedicacme.com Interventional Cardiology 2015: 30TH Annual International Symposium March 1–6, 2015 Physician/Industry Resident/Fellow/Nurse $1,050 Through January 16, 2015 $550 Through January 16, 2015 $1,250 After January 16, 2015 $750 After January 16, 2015 PAYM EN T All fees in US dollars drawn on US banks: Check Enclosed Visa/MasterCard American Express REGISTR ATI O N CREDIT CARD NUMBER EXPIRATION DATE Discover SIGNATURE FIRST/LAST NAME MD RN HOSPITAL/COMPANY MAILING ADDRESS CITY/STATE/ZIP/COUNTRY TELEPHONEFAX EMAIL ADDRESS Card SPECIALTY SEND TO Laurel Steigerwald, Promedica International CME 300 Carlsbad Village Drive, Suite 108A-326, Carlsbad, CA 92008 Tel: (760) 720-2263, Fax: (760) 720-6263 e-mail: [email protected] CCP Interesting and inspiring talks and very engaged discussions with top shots in a perfect environment. This meeting is one of the best in the world for international networking and invasive cardiology! Excellent content and a most thorough presentation and discussion of the important issues in interventional medicine. The faculty was exceptional…the enthusiasm contagious! Great international view of different approaches to disease management. One of the best programs available in interventional cardiology! HERE’S WHAT THEY’RE SAYING Promedica International CME 300 Carlsbad Village Drive, Suite 108A-326 Carlsbad, CA 92008 Presort Standard U.S. Postage PAID Permit 1948 San Diego CA
